Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.

Abou Alaiwi S, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, Steinharter JA, Nuzzo PV, Flippot R, Martinez-Chanza N, Wei X, McGregor BA, Kaymakcalan MD, Heng DYC, Bilen MA, Choueiri TK, Harshman LC.

J Immunother Cancer. 2020 Feb;8(1). pii: e000144. doi: 10.1136/jitc-2019-000144.

2.

The brain in pediatric chronic kidney disease-the intersection of cognition, neuroimaging, and clinical biomarkers.

Harshman LA, Hooper SR.

Pediatr Nephrol. 2020 Jan 2. doi: 10.1007/s00467-019-04417-1. [Epub ahead of print] Review.

PMID:
31897717
3.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD.

Ann Oncol. 2019 Nov 1;30(11):1841. doi: 10.1093/annonc/mdz214. No abstract available.

PMID:
31868903
4.

A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma.

Nassar AH, Mouw KW, Jegede O, Shinagare AB, Kim J, Liu CJ, Pomerantz M, Harshman LC, Van Allen EM, Wei XX, McGregor B, Choudhury AD, Preston MA, Dong F, Signoretti S, Lindeman NI, Bellmunt J, Choueiri TK, Sonpavde G, Kwiatkowski DJ.

Br J Cancer. 2020 Feb;122(4):555-563. doi: 10.1038/s41416-019-0686-0. Epub 2019 Dec 20.

PMID:
31857723
5.

Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma.

Nassar AH, Abou Alaiwi S, AlDubayan SH, Moore N, Mouw KW, Kwiatkowski DJ, Choueiri TK, Curran C, Berchuck JE, Harshman LC, Nuzzo PV, Chanza NM, Van Allen E, Esplin ED, Yang S, Callis T, Garber JE, Rana HQ, Sonpavde G.

Genet Med. 2019 Dec 17. doi: 10.1038/s41436-019-0720-x. [Epub ahead of print]

PMID:
31844177
6.

Chronic Kidney Disease: Treatment of Comorbidities I: (Nutrition, Growth, Neurocognitive Function, and Mineral Bone Disease).

Kogon AJ, Harshman LA.

Curr Treat Options Pediatr. 2019 Jun 15;5:78-92. doi: 10.1007/s40746-019-00152-9. Epub 2019 Apr 15.

PMID:
31840017
7.

Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.

McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, Signoretti S, Hirsch MS, Steinharter JA, Bakouny Z, Flippot R, Wei XX, Choudhury A, Kilbridge K, Freeman GJ, Van Allen EM, Harshman LC, McDermott DF, Vaishampayan U, Choueiri TK.

J Clin Oncol. 2020 Jan 1;38(1):63-70. doi: 10.1200/JCO.19.01882. Epub 2019 Nov 13.

PMID:
31721643
8.

Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.

Lalani AA, Xie W, Braun DA, Kaymakcalan M, Bossé D, Steinharter JA, Martini DJ, Simantov R, Lin X, Wei XX, McGregor BA, McKay RR, Harshman LC, Choueiri TK.

Eur Urol Oncol. 2019 Sep 24. pii: S2588-9311(19)30142-7. doi: 10.1016/j.euo.2019.09.001. [Epub ahead of print]

PMID:
31562048
9.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC; RISC Investigators.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30001-X. doi: 10.1016/j.euo.2018.12.013. [Epub ahead of print]

PMID:
31411990
10.

Chronic Kidney Disease: A Life Course Health Development Perspective.

Brophy PD, Charlton JR, Bryan Carmody J, Reidy KJ, Harshman L, Segar J, Askenazi D, Shoham D, Bagby SP.

In: Halfon N, Forrest CB, Lerner RM, Faustman EM, editors. Handbook of Life Course Health Development [Internet]. Cham (CH): Springer; 2018.
2017 Nov 21.

11.

Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.

Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Théodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A; RISC Investigators.

Eur Urol. 2019 Oct;76(4):425-429. doi: 10.1016/j.eururo.2019.06.032. Epub 2019 Jul 11.

PMID:
31303258
12.

Changes in lipid classes of Drosophila melanogaster in response to selection for three stress traits.

Ko L, Harshman L, Hangartner S, Hoffmann A, Kachman S, Black P.

J Insect Physiol. 2019 Aug - Sep;117:103890. doi: 10.1016/j.jinsphys.2019.103890. Epub 2019 May 30.

PMID:
31153895
13.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD.

Cancer. 2019 Sep 15;125(18):3155-3163. doi: 10.1002/cncr.32169. Epub 2019 May 31.

14.

Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer.

Nabel CS, Severgnini M, Hung YP, Cunningham-Bussel A, Gjini E, Kleinsteuber K, Seymour LJ, Holland MK, Cunningham R, Felt KD, Vivero M, Rodig SJ, Massarotti EM, Rahma OE, Harshman LC.

Oncologist. 2019 Aug;24(8):1013-1021. doi: 10.1634/theoncologist.2018-0633. Epub 2019 May 14.

15.

Developing a Research Mentorship Program: The American Society of Pediatric Nephrology's Experience.

Vasylyeva TL, Díaz-González de Ferris ME, Hains DS, Ho J, Harshman LA, Reidy KJ, Brady TM, Okamura DM, Samsonov DV, Wenderfer SE, Hartung EA.

Front Pediatr. 2019 Apr 24;7:155. doi: 10.3389/fped.2019.00155. eCollection 2019.

16.

Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?

Martinez Chanza N, Tripathi A, Harshman LC.

Curr Treat Options Oncol. 2019 May 3;20(5):44. doi: 10.1007/s11864-019-0639-0. Review.

PMID:
31054006
17.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.

PMID:
30968729
18.

The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer.

Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD.

Oncologist. 2019 Oct;24(10):1348-1355. doi: 10.1634/theoncologist.2018-0739. Epub 2019 Apr 1.

19.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

20.

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME.

J Clin Oncol. 2019 Apr 10;37(11):923-931. doi: 10.1200/JCO.18.01777. Epub 2019 Feb 27.

PMID:
30811282
21.

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.

Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, Choueiri TK, Sonpavde G, Kwiatkowski DJ.

Clin Cancer Res. 2019 Apr 15;25(8):2458-2470. doi: 10.1158/1078-0432.CCR-18-3147. Epub 2018 Dec 28.

PMID:
30593515
22.

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN.

Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018.

23.

Academic achievement in children with chronic kidney disease: a report from the CKiD cohort.

Harshman LA, Johnson RJ, Matheson MB, Kogon AJ, Shinnar S, Gerson AC, Warady BA, Furth SL, Hooper SR.

Pediatr Nephrol. 2019 Apr;34(4):689-696. doi: 10.1007/s00467-018-4144-7. Epub 2018 Nov 17.

PMID:
30448874
24.

Tumor fraction in cell-free DNA as a biomarker in prostate cancer.

Choudhury AD, Werner L, Francini E, Wei XX, Ha G, Freeman SS, Rhoades J, Reed SC, Gydush G, Rotem D, Lo C, Taplin ME, Harshman LC, Zhang Z, O'Connor EP, Stover DG, Parsons HA, Getz G, Meyerson M, Love JC, Hahn WC, Adalsteinsson VA.

JCI Insight. 2018 Nov 2;3(21). pii: 122109. doi: 10.1172/jci.insight.122109.

25.

Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer.

Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ.

Clin Genitourin Cancer. 2019 Feb;17(1):32-37. doi: 10.1016/j.clgc.2018.09.022. Epub 2018 Oct 4.

PMID:
30348512
26.

Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy.

Berg S, Cole AP, Fletcher SA, Pucheril D, Nabi J, Lipsitz SR, Chang SL, Sun M, Noldus J, Harshman LC, Choueiri TK, Trinh QD.

Urol Oncol. 2018 Sep;36(9):400.e15-400.e22. doi: 10.1016/j.urolonc.2018.06.005.

PMID:
30274640
27.

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.

Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE.

Br J Cancer. 2018 Sep;119(6):707-712. doi: 10.1038/s41416-018-0261-0. Epub 2018 Sep 17.

28.

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer.

Choudhury AD, Gray KP, Supko JG, Harshman LC, Taplin ME, Pace AF, Farina M, Zukotynski KA, Bernard B, Kantoff PW, Pomerantz M, Sweeney C.

Prostate. 2018 Jun 7. doi: 10.1002/pros.23662. [Epub ahead of print]

29.

Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases.

McKay RR, Bossé D, Gray KP, Michaelson MD, Krajewski K, Jacene HA, Walsh M, Bellmunt J, Pomerantz M, Harshman LC, Choueiri TK.

Clin Cancer Res. 2018 Sep 1;24(17):4081-4088. doi: 10.1158/1078-0432.CCR-17-3577. Epub 2018 May 30.

30.

Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.

Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A.

Eur Urol. 2018 Nov;74(5):611-620. doi: 10.1016/j.eururo.2018.05.002. Epub 2018 May 18.

PMID:
29784193
31.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

32.

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ.

Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29.

33.

Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (CFH) gene family.

Cantsilieris S, Nelson BJ, Huddleston J, Baker C, Harshman L, Penewit K, Munson KM, Sorensen M, Welch AE, Dang V, Grassmann F, Richardson AJ, Guymer RH, Graves-Lindsay TA, Wilson RK, Weber BHF, Baird PN, Allikmets R, Eichler EE.

Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4433-E4442. doi: 10.1073/pnas.1717600115. Epub 2018 Apr 23.

34.

Physiological Approach to Sodium Supplementation in Preterm Infants.

Segar DE, Segar EK, Harshman LA, Dagle JM, Carlson SJ, Segar JL.

Am J Perinatol. 2018 Aug;35(10):994-1000. doi: 10.1055/s-0038-1632366. Epub 2018 Feb 27.

35.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

36.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

37.

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS.

Clin Genitourin Cancer. 2018 Jun;16(3):213-218. doi: 10.1016/j.clgc.2017.11.004. Epub 2017 Dec 6.

38.

Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.

Harshman LC, Xie W, Moreira RB, Bossé D, Ruiz Ares GJ, Sweeney CJ, Choueiri TK.

Cancer. 2018 Mar 1;124(5):925-933. doi: 10.1002/cncr.31154. Epub 2017 Dec 19.

39.

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.

40.

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ; ECOG-ACRIN 3805 Investigators.

J Clin Oncol. 2018 Feb 1;36(4):376-382. doi: 10.1200/JCO.2017.75.3921. Epub 2017 Dec 20.

41.

Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.

Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium Group.

Clin Genitourin Cancer. 2018 Apr;16(2):e483-e490. doi: 10.1016/j.clgc.2017.10.012. Epub 2017 Nov 1.

PMID:
29158079
42.

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O'Connor EP, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M.

Nat Commun. 2017 Nov 6;8(1):1324. doi: 10.1038/s41467-017-00965-y.

43.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.

Ann Oncol. 2018 Feb 1;29(2):361-369. doi: 10.1093/annonc/mdx692. Erratum in: Ann Oncol. 2019 Nov;30(11):1841.

44.

Pyrethroid Susceptibility Has Been Maintained in the Dengue Vector, Aedes aegypti (Diptera: Culicidae), in Queensland, Australia.

Endersby-Harshman NM, Wuliandari JR, Harshman LG, Frohn V, Johnson BJ, Ritchie SA, Hoffmann AA.

J Med Entomol. 2017 Nov 7;54(6):1649-1658. doi: 10.1093/jme/tjx145.

PMID:
28981684
45.

Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Cheng HH, Abida W, Ellis L, Harshman LC, Spratt DE, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Nov;77(15):1478-1488. doi: 10.1002/pros.23424. Epub 2017 Sep 18. Review.

46.

Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.

Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY; RISC Investigators.

Clin Genitourin Cancer. 2017 Aug 24. pii: S1558-7673(17)30242-2. doi: 10.1016/j.clgc.2017.08.001. [Epub ahead of print]

47.

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Acta Oncol. 2018 Apr;57(4):491-497. doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30.

PMID:
28853615
48.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK.

J Immunother Cancer. 2017 Aug 15;5(1):66. doi: 10.1186/s40425-017-0273-y.

49.

The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.

Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW.

Prostate. 2017 May;77(13):1303-1311. doi: 10.1002/pros.23390. Epub 2017 Aug 1.

50.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2019 Mar;5(2):242-249. doi: 10.1016/j.euf.2017.05.006. Epub 2017 Jun 3.

PMID:
28753897

Supplemental Content

Loading ...
Support Center